valu usd unless otherwis note
solid quarter lower estim buyer
pullback
view constant currenc revenu growth remain solid evidenc
result segment-level guidanc underli
oper margin expans continu assum
currenc volatil remain subdu howev currenc higher tax
rate lead lower ep lower ep tweak
buyer weak
revenu exceed estim ww revenu
y/i compar cc rbce consensu
revenu growth adjust neg impact
hurrican maria sequenti improv driven
better perform mitg rtg dg fx volatil januari
exacerb hedg loss nullifi underli improv
oper margin ep y/i cc penni miss
versu estim fx-relat line consensu
surgic innov si pain therapi diabet account
upsid revenu estim within si upsid
came new product signia power surgic stapl system
ligasur vessel seal instrument stabl procedur volum
emerg market pain therapi launch intelli
evolv workflow strong growth pump target drug
deliveri led y/i growth compar declin
diabet minim system shipment start
earnest new patient order prioriti access
custom satisfi sensor suppli return normal
forecast compar cc revenu growth
ep growth line expect fx
tax rate result lower report ep revenu guidanc translat
ww revenu includ favor currenc
contribut ep guidanc give rang
includ fx headwind revenu forecast increas
reflect bigger fx tailwind howev lower
ep owe larger expect hedg
loss slightli higher tax rate upsid project
come new product exposur faster-grow med-tech market
stronger emerg market perform
guidanc hsd cc ep growth guidanc project cc
revenu growth ep new ww revenu estim
prior increas mainli due currenc
two-third balanc higher oper growth assum
cc ep growth adjust base exclud
divestitur includ fx tailwind yield rang
howev manag call sever headwind
ep result decreas ep estim
price prior trade day market close estimate unless otherwis note
four segment particip acceler
compar cc revenu growth follow y/i
growth ww revenu forecast
growth top end guidanc
put revenu growth close upper end
rang includ fx headwind
estim
estim look reason base initi
comment next year outlook mid-single-digit cc
revenu growth oper margin expans high-
single-digit ep growth figur manag preliminari
includ fx start point ep
growth rang appear reason impli
rang includ fx
intermediate-risk label expans prove
import catalyst tavr market growth interim result
surtavi trial present annual meet
american colleg cardiolog one-year result
patient present tct
show surtavi met primari end point non-
inferior surgeri furthermor corevalve/corevalv
evolut result trend favor surgeri
sever import clinic procedur outcom
receiv fda approv new indic juli
number busi within segment
well restor therapi group rtg
neurovascular neurosurgeri advanc energi
worth highlight spine recov minim
invas therapi group mitg launch new
product advanc advanc stapl
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim key assumpt
underli ep estim mid-single-digit revenu
compound-annual-growth-rate next three fiscal year exclud
neg impact hurrican maria relat
disrupt basi point oper margin
expans three year excess free cash flow
 deploy primarili debt repay
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu compound-annual-growth-rate next three
fiscal year achiev combin
accret superior perform key product
stent leadless pacemak brain therapi diabet
basi point oper margin expans
three year
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu compound-annual-growth-rate next three
fiscal year basi point oper margin
expans three year meaning
price target base ep estim y/i
reli success new product launch past month acceler
growth target multipl lower averag price-to-earnings large-cap
med-tech peer trade around estim reflect histor
discount compani price target basi outperform rate
risk rate price target
lacklust new product cycl sale growth increasingli support
stand-alon new product cycl includ attain performa quadripolar crt-d
reveal linq micra pacemak admir dcb corevalv evolut estim could
neg affect sale new product come expect
inabl achiev target cost save manag believ achiev least
pre-tax cost synergi end cost synergi fail
materi project ep growth estim could high
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur
weak util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
